Business Context and Reporting Period
Company: IDEAYA Biosciences, Inc. (IDYA)
Filing Type: Form 8-K (Current Report)
Date: September 23, 2024
Subject: Item 8.01 Other Events – Clinical Update on darovasertib for neoadjuvant uveal melanoma (UM) and FDA guidance.
Key Financial Metrics
This filing is a clinical update and does not contain financial statements. The text does not provide values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes and Clinical Data
The Company announced interim data from a Phase 2 trial (IDE196-009) and an investigator-sponsored trial (IST) evaluating darovasertib in neoadjuvant UM. Key clinical findings include:
- Study Population: 49 total evaluable patients (31 enucleation, 18 plaque brachytherapy).
- Tumor Shrinkage: Approximately 59% (29/49) of patients achieved ≥20% ocular tumor shrinkage; approximately 49% (24/49) achieved ≥30% shrinkage.
- Eye Preservation: Approximately 61% eye preservation rate observed in enucleation patients.
- Visual Preservation: Evidence of reduced radiation requirements in plaque brachytherapy patients.
- Safety Profile: Manageable adverse events (AEs). 11% of patients experienced Grade 3+ AEs; 5% experienced serious AEs. Discontinuation rate was 3%. Common AEs included diarrhea, nausea, vomiting, and fatigue.
Guidance, Outlook, and Regulatory Strategy
Following a Type C meeting with the FDA, the Company plans to initiate a registration-enabling Phase 3 randomized clinical trial.
- Trial Design: Projected enrollment of approximately 400 patients across two cohorts (enucleation and plaque brachytherapy).
- Primary Endpoints: Eye preservation rate for enucleation patients (targeting >10% lower bound with 95% confidence); Time to vision loss for plaque brachytherapy patients.
- Secondary Endpoints: No detriment to Event-Free-Survival (EFS).
- Dosing: 300mg BID identified as the move-forward dose.
- Market Opportunity: Neoadjuvant UM represents a potential annual incidence of ~12,000 patients in North America, Europe, and Australia.
- Timeline: Approximately two years of data maturity projected for initial EFS readout in high-risk populations.
Investor Verification Checklist
- Confirm the final Phase 3 trial design and enrollment targets following ongoing FDA discussions.
- Verify the Company's cash runway and capital requirements to fund the Phase 3 trial and operations.
- Review the specific economic obligations under the exclusive worldwide license with Novartis.
- Monitor the timeline for the initiation of the Phase 3 trial and potential modifications to the protocol.
- Assess the risk factors related to the translation of Phase 2 data to Phase 3 outcomes and regulatory approval.